The United Kingdom's Week 3 2026 Flu Report: Early Onset, Rapid Decline

1. Introduction

The winter of 2025-2026 has marked a pivotal moment in the post-pandemic trajectory of seasonal respiratory viruses. After several years of disrupted seasonality and suppressed circulation following the global emergence of SARS-CoV-2, influenza has returned with a distinct and challenging character. In the United Kingdom, the season has been defined by an unusually early onset and a rapid acceleration of cases, driven primarily by a drifted genetic variant of Influenza A(H3N2) known as subclade K (or J.2.4.1). As of January 22, 2026, the United Kingdom finds itself on the descending slope of a substantial epidemic wave, a status that stands in contrast to the persistent and elevated activity observed across the Atlantic in the United States and in various regions of East Asia.

This report provides an exhaustive analysis of the current influenza landscape, synthesizing data from national surveillance bodies including the UK Health Security Agency (UKHSA), the U.S. Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO). It explores the complex virological dynamics of the dominant H3N2 subclade K, examining the mechanisms of antigenic drift that have led to a mismatch with the season's vaccine formulations. Furthermore, it investigates the broader "syndemic" context, where influenza co-circulates with Respiratory Syncytial Virus (RSV), COVID-19, and a surging Norovirus, creating multifaceted pressures on healthcare systems. By juxtaposing the UK experience with global data, this article aims to elucidate the unique epidemiological signature of the 2025-2026 season and its implications for future public health preparedness.

2. The United Kingdom: Current Status and Epidemiological Trajectory

2.1. The Trajectory of the 2025-2026 Wave

As of late January 2026, the United Kingdom is witnessing a decided contraction in influenza activity. The surveillance data for Week 3 (ending January 18, 2026) and early indicators for Week 4 (ending January 25, 2026) describe a consistent downward trend across all primary indicators, suggesting that the peak of the epidemic occurred in late December 2025 and early January 2026.¹ This decline is observed in both community transmission metrics and severe disease outcomes.

Laboratory Surveillance and Positivity Rates: The cornerstone of UK influenza monitoring is the Respiratory DataMart system, which aggregates laboratory results from a network of sentinel public health laboratories. The data indicates a sharp reduction in viral prevalence. In Week 3 of 2026, the overall influenza positivity rate fell to 10.5%, a notable decrease from 11.8% in the preceding week and 14.1% in Week 2.¹ This reduction follows the classic Bell curve of seasonal epidemics, where the depletion of susceptible hosts—accelerated by the holiday mixing patterns—leads to a burnout of the transmission chain.

The General Practice (GP) sentinel swabbing scheme, which provides a window into symptomatic illness in the community, mirrors this trend. Positivity among patients presenting to primary care with influenza-like illness (ILI) dropped to 15.8% in Week 3, down from 18.1% in Week 2.¹ This metric is particularly significant as it filters out the "worried well" and focuses on clinically relevant respiratory episodes. The synchronization of the GP and hospital laboratory data reinforces the conclusion that the decline is a genuine epidemiological phenomenon rather than an artifact of testing behaviors.

2.2. Healthcare Utilization and Systemic Pressure

While the viral transmission metrics are improving, the operational reality for the National Health Service (NHS) remains complex. The lag between infection and hospitalization, and subsequently between hospitalization and discharge, means that the healthcare burden dissipates more slowly than the community infection rate.

Hospital Admissions: The rate of hospital admissions for confirmed influenza is decreasing but remains non-negligible. In Week 3, the admission rate stood at 4.85 per 100,000 population, a relief compared to the 6.03 per 100,000 recorded in Week 2.¹ This reduction translates to hundreds of fewer patients requiring bed space daily, a critical reprieve for hospitals that have been operating at near-maximum capacity.

Critical Care Metrics: Perhaps the most reassuring data point is the decline in admissions to Intensive Care Units (ICU) and High-Dependency Units (HDU). The rate decreased to 0.18 per 100,000 in Week 3, down from 0.21 per 100,000.¹ H3N2-dominated seasons are notoriously severe for the elderly, often leading to higher mortality and ICU utilization than H1N1 or B seasons. The decline in this specific metric suggests that the wave of severe physiological decompensation associated with the peak of infection has crested.

The "Hidden" Pressures: However, the "status" of the flu cannot be divorced from the wider hospital context. Surveillance reports highlight a concurrent surge in Norovirus, a gastrointestinal pathogen that causes outbreaks of vomiting and diarrhea. Norovirus cases in NHS hospitals increased by 57% in early January.³ The intersection of a declining flu wave and a rising Norovirus wave complicates bed management; flu requires respiratory isolation (droplet precautions), while Norovirus requires contact isolation and rigorous environmental decontamination. This "bed blocking" effect means that even as flu numbers fall, the functional capacity of the NHS remains strained, with at least ten hospital trusts declaring critical incidents in mid-January.³

2.3. Demographic Disparities in Infection and Severity

The 2025-2026 season has reaffirmed the age-stratified impact of the H3N2 virus. The surveillance data reveals a stark dichotomy between the drivers of transmission and the victims of severe disease.

The Engines of Transmission: The highest rates of infection have been consistently identified in adolescents and young adults. In Week 2, the positivity rate for those aged 15 to 24 years was a striking 20.6%.² By Week 3, this had decreased to 17.3%, yet it remained the highest of any age cohort.¹ This demographic is highly mobile and socially active, serving as the primary vector for community dissemination. The high positivity here suggests that schools and universities were major hubs for the amplification of the subclade K variant.

The Burden of Severity: In contrast, the severe outcomes are heavily skewed towards the geriatric population. Hospital admission rates and positivity in hospital settings are highest in those aged 85 years and over. In Week 3, SARS-CoV-2 positivity was also highest in this group at 2.3% ¹, indicating that the oldest citizens are facing a "syndemic" risk—simultaneous exposure to influenza, COVID-19, and RSV. The immune senescence in this population makes them particularly vulnerable to the drifted H3N2 strain, as their residual immunity from historical infections is less effective against the novel mutations of subclade K.

2.4. Regional Uniformity

Geographically, the decline in influenza activity appears to be relatively uniform across the UK. Unlike some seasons where the epidemic wave moves from north to south or urban to rural, the 2025-2026 wave—fueled by the rapid travel and mixing of the Christmas period—appears to have saturated the population nationally. All regions reported decreasing or stable trends in ILI indicators ¹, suggesting a synchronized national exit from the epidemic phase.

3. The Virological Driver: Influenza A(H3N2) Subclade K

To understand the 2025-2026 season, one must examine the specific viral agent responsible: the Influenza A(H3N2) subclade K. This variant, technically classified within clade 2a.3a.1, represents a significant evolutionary step for the virus and is the primary reason for the intense activity observed globally.⁴

3.1. Evolutionary Origins and Classification

The origins of subclade K can be traced to the 2025 Southern Hemisphere season. Australia and New Zealand experienced a prolonged and late-peaking influenza season in 2025.⁵ Towards the end of the Australian winter (August-September), surveillance systems detected a replacement of the previously dominant strains with a new variant. This variant, initially termed J.2.4.1 and later reclassified as subclade K, showed a fitness advantage that allowed it to persist and spread even as the season should have been waning.⁵

From its foothold in Oceania, subclade K spread globally via international travel, seeding the Northern Hemisphere autumn. By November 2025, it had been detected in over 34 countries ⁶, effectively outcompeting other H3N2 lineages and setting the stage for the Northern Hemisphere winter.

3.2. Genomic Architecture and Mutations

Subclade K is defined by a specific constellation of amino acid substitutions in the Hemagglutinin (HA) protein, the viral surface antigen that is the primary target for neutralizing antibodies. Genomic sequencing has identified several critical mutations relative to the vaccine reference strains:

• T135K: This mutation involves the loss of a glycosylation site. Glycans (sugar molecules) on the surface of the virus can shield antigenic sites from the immune system. The loss or gain of these sites can unmask or mask epitopes, altering how antibodies bind.⁷

• S144N: Located in Antigenic Site A, a major target for the immune response. A change here can significantly reduce the binding affinity of antibodies generated by previous infection or vaccination.⁷

• I160K: Another mutation affecting the structural loops of the HA protein.⁷

• Other substitutions: K2N, N158D, Q173R, K189R, T328A, and S378N collectively contribute to the antigenic drift of this variant.⁷

3.3. Mechanisms of Antigenic Drift and "Mismatch"

These mutations have resulted in a virus that is "antigenically distinct" from the strains selected for the 2025-2026 influenza vaccines. The Northern Hemisphere vaccine contains an H3N2 component based on A/Croatia/10136RV/2023 (for egg-based vaccines) or A/District of Columbia/27/2023 (for cell-based vaccines).⁸

Laboratory assays, specifically hemagglutination inhibition (HI) tests using ferret antisera, confirm the mismatch. Antibodies produced against the A/Croatia-like vaccine strain show significantly reduced reactivity (often >32-fold reduction in titers) when tested against the circulating subclade K viruses.⁹ This biological mismatch means that the neutralizing antibodies induced by the vaccine are less efficient at "locking on" to the invading virus, allowing it to infect cells and replicate. This explains the high infection rates (high positivity) observed in the UK and US despite vaccination programs.

3.4. Transmissibility versus Severity

Crucially, the "success" of subclade K appears to be driven by its transmissibility (immune escape) rather than intrinsic virulence. Both the European Centre for Disease Prevention and Control (ECDC) and the WHO have stated that there is no evidence that subclade K causes more severe disease per infection than other H3N2 variants.¹⁰ The virus does not appear to replicate deeper in the respiratory tract or trigger more aggressive cytokine storms. The strain on healthcare systems is a function of volume: a more transmissible virus infects a larger number of people, leading to a higher absolute number of hospitalizations, even if the hospitalization rate per 1,000 infections remains constant.

4. Comparative Epidemiology: The United States

While the United Kingdom is exiting its peak, the United States presents a more heterogeneous and persistent picture of influenza activity. As of mid-January 2026, the US continues to report elevated levels of transmission, with significant regional variation.

4.1. National Activity and Timing

In the United States, influenza activity remains high nationally. For Week 1 of 2026 (ending January 10), the percentage of respiratory specimens testing positive for influenza at clinical laboratories was 18.6%.¹² While this represents a decrease from the peak of 24.6% seen in late December, it is significantly higher than the ~10% currently seen in the UK. This suggests that the US epidemic curve is lagging behind the UK's, or that the post-holiday plateau is more sustained.

The CDC reports that activity is "elevated and continues to increase" in some areas, while showing signs of decline in others.¹⁴ The number of jurisdictions (states and territories) reporting "high" or "very high" activity remains substantial, at 36 out of 54, though this is a drop from 45 in the previous week.¹³

4.2. Regional Heterogeneity

Unlike the uniform decline in the UK, the US shows distinct regional patterns.

• Region 2 (NY, NJ): Reported the highest positivity rate at 22.9%.¹² This suggests that the densely populated Northeast is still in the thick of the epidemic.

• Region 8 (Mountain West): Reported an extremely high positivity of 31.7% in late December ¹⁵, indicating an intense, focused outbreak in that area.

• Region 9 (West Coast/Pacific): Reported the lowest positivity at 11.5%.¹²

This patchiness is characteristic of the US geography, where distinct climate zones and population centers can sustain independent epidemic waves that overlap to create a prolonged national season.

4.3. Pediatric Impact

A tragic differentiator in the US data is the explicit reporting of pediatric mortality. In Week 1 of 2026 alone, 15 influenza-associated pediatric deaths were reported, bringing the season total to 32.¹² H3N2 seasons are historically dangerous for children, not necessarily due to respiratory failure alone, but due to complications such as sepsis, coinfection (e.g., with Staphylococcus aureus), and neurological events. The high pediatric death toll in the US underscores the severity of the subclade K wave in non-immune populations, even if the overall virulence is considered standard.

4.4. Strain Composition: A Mirror Image

Despite the epidemiological differences, the virological picture in the US is identical to that of the UK. The season is overwhelmingly dominated by Influenza A(H3N2).

• Dominance: In Week 1, 93.0% of positive specimens were Influenza A, and of those subtyped, the vast majority were H3N2.¹²

• Subclade K: The CDC's genetic characterization confirms that 90.9% of analyzed H3N2 viruses belong to subclade K (clade 2a.3a.1).¹² This confirms that the US and UK are fighting the same viral enemy, with differences in outcomes likely driven by healthcare system structures, population density, and vaccination coverage rates rather than viral genetics.

5. The Global Context: Europe and Asia

The influenza season is a global phenomenon, and the 2025-2026 data highlights the interconnectedness of the Northern Hemisphere's viral ecosystem.

5.1. The European "Early Wave"

Continental Europe has largely mirrored the UK's experience. The WHO European Region reported an unusually early start to the season, with activity picking up 3-4 weeks earlier than the historical average.¹¹ By December 2025, over half of the reporting countries—including Ireland, Slovenia, and Serbia—were seeing positivity rates exceeding 50% in sentinel samples.¹¹

This "early wave" phenomenon suggests that subclade K is a highly efficient colonizer. Once introduced into a population, it reaches epidemic thresholds faster than typical drift variants. Reports from France indicate that while the season started with some H1N1 activity, it was rapidly overtaken by H3N2 subclade K as the season progressed.¹⁶ The synchronization of the European wave points to high levels of cross-border transmission within the EU.

5.2. East Asia: Divergent Patterns

In East Asia, the dominance of H3N2 is also evident, though local dynamics vary.

• Japan: Surveillance from January 2026 shows H3N2 as the predominant strain. Early data indicates that subclade K accounts for 90% of flu samples in Japan, similar to the UK and US.¹⁷ The Japanese sentinel system is reporting increasing case numbers, with concerns about a peak coinciding with mid-winter gatherings.

• China: The situation in China is more complex. Surveillance reports from the Chinese Center for Disease Control and Prevention (China CDC) for Week 1 of 2026 show a transition. While H3N2 is present, there has been significant circulation of H1N1 (A/Victoria-like) in the preceding months.¹⁸ However, recent weeks show a rising proportion of H3N2, with 72.5% of characterized H3N2 viruses matching the cell-based vaccine reference (A/District of Columbia), which is the clade containing the subclade K drift variants.¹⁸ This suggests China may be in a transition phase from an H1N1-heavy autumn to an H3N2-heavy winter.

• Taiwan: The Taiwan CDC warned in late January 2026 that the country was entering a new epidemic period, driven by A(H3N2). They predicted a peak around the Lunar New Year, with hospital visits nearing 130,000 per week.¹⁹ This highlights the potential for holiday-related amplification in Asian regions, similar to the Thanksgiving/Christmas acceleration seen in the West.

6. Vaccine Science: The 2025-2026 Mismatch and Effectiveness

The interaction between the drifted subclade K virus and the 2025-2026 influenza vaccines is a central theme of this season's scientific discourse.

6.1. The Selection Timeline and the "Lag"

The root of the "mismatch" lies in the inherent timeline of influenza vaccine production. The strains for the Northern Hemisphere 2025-2026 season were selected by the WHO in February 2025.²⁰ At that time, subclade K had not yet emerged as a dominant global threat. It was only in August 2025—six months later—that the variant surged in Australia.⁵ By then, manufacturers were already producing millions of doses of the A/Croatia-like vaccine. This 6-month lag is the Achilles' heel of egg-based and even cell-based manufacturing, leaving the global population vulnerable to late-breaking variants.

6.2. Real-World Effectiveness (VE)

Despite the laboratory evidence of antigenic mismatch, real-world data provides a degree of reassurance. "Mismatch" does not mean "zero protection."

• UKHSA Estimates: Early vaccine effectiveness (VE) estimates from the UK suggest the vaccine is performing relatively well against severe disease. VE against hospitalization is estimated at 70-75% for children and 30-40% for adults.²¹

• European Data: Interim studies from France corroborate this, showing VE against confirmed influenza at roughly 36% for all ages, but higher (57%) in children.¹⁶

The Mechanism of Residual Protection:

How does a mismatched vaccine work? The answer lies in the breadth of the immune response.

1. Polyclonal Antibodies: Even if the vaccine-induced antibodies fail to bind the mutated tip of the HA protein, they may bind to other, more conserved regions of the virus.

2. T-Cell Immunity: Vaccination stimulates CD4+ and CD8+ T-cells. These cells do not prevent the virus from entering the body (infection), but they are excellent at identifying and killing infected cells. This limits viral replication and prevents the infection from progressing to severe pneumonia. This explains the "decoupling" observed in the UK: high case numbers (infection) but a manageable rate of ICU admissions (severe disease).

6.3. The Extinction of B/Yamagata

A historic shift in influenza epidemiology is the apparent extinction of the Influenza B/Yamagata lineage. This lineage has not been definitively detected in global circulation since March 2020. In the UK and US 2025-2026 season, 100% of identified Influenza B viruses belong to the Victoria lineage.¹ Consequently, public health bodies have moved to trivalent vaccines, removing the Yamagata component.²³ This simplifies vaccine production and removes an antigen that is no longer clinically relevant, marking the first time in decades that the target list for flu vaccines has shrunk rather than expanded.

7. Clinical Management and Antiviral Susceptibility

With high transmission levels, the role of antiviral therapeutics becomes critical.

• Susceptibility: Encouragingly, surveillance data from the US, UK, and China indicates that virtually all circulating influenza viruses (including subclade K) remain susceptible to neuraminidase inhibitors (oseltamivir, zanamivir) and the endonuclease inhibitor (baloxavir).¹⁴

• Resistance: Resistance markers are extremely rare. In China, all tested H3N2 viruses were sensitive to these drugs.¹⁸

• Clinical Guidelines: Given the efficacy of antivirals, guidelines in the UK and Europe emphasize the early treatment of high-risk patients. Because the vaccine may not prevent infection due to the mismatch, early antiviral intervention serves as a critical second line of defense to prevent hospitalization in the elderly and immunocompromised.⁷

8. The Syndemic Context: Influenza in a Multi-Pathogen Winter

The status of influenza in January 2026 cannot be viewed in isolation. The UK and other nations are managing a complex "syndemic" environment.

• Norovirus: The surge in Norovirus in the UK ³ creates a logistical nightmare for hospitals. The simultaneous management of respiratory (flu) and gastrointestinal (norovirus) outbreaks requires rigorous and distinct infection control protocols, often reducing the effective bed capacity of wards.

• RSV: Respiratory Syncytial Virus continues to circulate, though it typically peaks earlier than flu. In Week 3, RSV positivity in the UK was decreasing but still notable at 6.4% ¹, continuing to drive pediatric admissions.

• COVID-19: SARS-CoV-2 has settled into a baseline pattern of circulation. In the UK, positivity is stable at around 1.8%, but significantly higher (2.3%) in the elderly.¹ While not causing the explosive waves of 2020-2022, it adds a constant baseline of respiratory pressure that reduces the system's resilience to flu surges.

• Mycoplasma: The US has also noted elevated cases of "walking pneumonia" caused by Mycoplasma pneumoniae ²⁴, adding another bacterial layer to the respiratory burden.

9. Conclusion

As of January 22, 2026, the United Kingdom is successfully navigating the tail end of a challenging influenza season. The H3N2 subclade K variant, having emerged from the Southern Hemisphere to dominate the globe, tested the resilience of the population and the healthcare system. Its ability to drift away from vaccine-induced immunity drove high infection rates, particularly among the young. However, the protection against severe disease held firm, preventing a catastrophic collapse of critical care services.

The comparison with the United States and Asia reveals a synchronized biological threat played out on different timelines. While the UK curve bends downward, the US remains in a phase of elevated transmission, and East Asia braces for holiday peaks. The global dominance of subclade K underscores the relentless evolution of the influenza virus and the necessity for a global, coordinated response.

Looking ahead, the 2025-2026 season serves as a powerful argument for the acceleration of vaccine technologies. The six-month lag that allowed subclade K to outmaneuver the global vaccine supply highlights the urgent need for faster, more responsive platforms like mRNA-based vaccines. Until then, the seasonal battle against influenza will remain a game of probability, surveillance, and clinical resilience.

Table 1: Comparative Influenza Indicators (Mid-January 2026)

Metric	United Kingdom	United States
Status (Jan 22)	Declining	Elevated / Mixed
Positivity Rate	10.5% (Week 3)	18.6% (Week 1)
Dominant Strain	A(H3N2) (~88%)	A(H3N2) (~93%)
Key Variant	Subclade K (J.2.4.1)	Subclade K (J.2.4.1)
Pediatric Impact	High transmission, low mortality data	High transmission, 32 deaths
Vaccine Match	Mismatched (Antigenic Drift)	Mismatched (Antigenic Drift)
Influenza B	Rare (<1%), No Yamagata	Rare (5.8%), No Yamagata

Data Sources: UKHSA ¹; CDC FluView.¹²

Table 2: Key Mutations in H3N2 Subclade K (J.2.4.1)

Mutation	Viral Protein	Functional Impact
T135K	Hemagglutinin (HA)	Loss of Glycosylation: Unmasks/Alters antigenic surface, reducing antibody recognition.
S144N	Hemagglutinin (HA)	Epitope Alteration: Changes Antigenic Site A, a primary target for neutralizing antibodies.
I160K	Hemagglutinin (HA)	Structural Change: Affects loop stability and antibody binding access.
N158D	Hemagglutinin (HA)	Antigenic Drift: Contributes to the distinct antigenic profile of the clade.

Source: ECDC Risk Assessment.⁷

Works cited

1. National flu and COVID-19 surveillance report: 22 January 2026 ..., accessed January 22, 2026, https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season/national-flu-and-covid-19-surveillance-report-22-january-2026-week-4

2. National flu and COVID-19 surveillance report: 15 January 2026 (week 3) - GOV.UK, accessed January 22, 2026, https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season/national-flu-and-covid-19-surveillance-report-15-january-2026-week-3

3. Flu admissions fall but norovirus on the rise as hospitals declare critical incidents, accessed January 22, 2026, https://www.bmj.com/content/392/bmj.s109

4. Genomic analysis report - influenza surveillance - Queensland Health, accessed January 22, 2026, https://www.health.qld.gov.au/__data/assets/pdf_file/0023/1361921/flu-genomic-analysis-report.pdf?version=01

5. 2025, the year that influenza surprised us | Doherty Website, accessed January 22, 2026, https://www.doherty.edu.au/news-events/news/2025-the-year-that-influenza-surprised-us

6. Extended influenza seasons in Australia and New Zealand in 2025 due to the emergence of influenza A(H3N2) subclade K viruses - PMC - NIH, accessed January 22, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12701333/

7. Assessing the risk of influenza for the EU/EEA in the context of increasing circulation of A(H3N2) subclade K - ECDC, accessed January 22, 2026, https://www.ecdc.europa.eu/sites/default/files/documents/influenza-risk-assessment-EU-EEA-circulation-AH3N2-subclade-K.pdf

8. Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season - FDA, accessed January 22, 2026, https://www.fda.gov/vaccines-blood-biologics/influenza-vaccine-composition-2025-2026-us-influenza-season

9. Early influenza virus characterisation and vaccine effectiveness in England in autumn 2025, a period dominated by influenza A(H3N2) subclade K - PMC - NIH, accessed January 22, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12639273/

10. New Flu Strain Sweeping Europe Says WHO; But Vaccines Remain Effective, ECDC Finds, accessed January 22, 2026, https://healthpolicy-watch.news/who-europe-warns-of-influenza-spread/

11. More than half of WHO European Region experiencing intense, early influenza season driven by new strain, accessed January 22, 2026, https://www.who.int/europe/news/item/17-12-2025-more-than-half-of-who-european-region-experiencing-intense--early-influenza-season-driven-by-new-strain

12. Weekly US Influenza Surveillance Report: Key Updates for Week 1 ..., accessed January 22, 2026, https://www.cdc.gov/fluview/surveillance/2026-week-01.html

13. US flu activity declining but remains high, accessed January 22, 2026, https://www.cidrap.umn.edu/influenza-general/us-flu-activity-declining-remains-high

14. Weekly US Influenza Surveillance Report: Key Updates for Week 52, ending December 27, 2025 | FluView | CDC, accessed January 22, 2026, https://www.cdc.gov/fluview/surveillance/2025-week-52.html

15. Weekly US Influenza Surveillance Report: Key Updates for Week 53, ending January 3, 2026 | FluView | CDC, accessed January 22, 2026, https://www.cdc.gov/fluview/surveillance/2025-week-53.html

16. Current flu vaccine provides moderate protection against severe disease, interim analyses suggest | CIDRAP, accessed January 22, 2026, https://www.cidrap.umn.edu/influenza-vaccines/current-flu-vaccine-provides-moderate-protection-against-severe-disease-interim

17. With an absent CDC and mismatched 'subclade K' flu strain, experts face upcoming season with uncertainty | CIDRAP, accessed January 22, 2026, https://www.cidrap.umn.edu/influenza-vaccines/absent-cdc-and-mismatched-subclade-k-flu-strain-experts-face-upcoming-season

18. Chinese Weekly Influenza Surveillance Report, accessed January 22, 2026, https://ivdc.chinacdc.cn/cnic/en/Surveillance/WeeklyReport/202601/P020260108326061121496.pdf

19. New flu epidemic period may begin this week: CDC - Taipei Times, accessed January 22, 2026, https://www.taipeitimes.com/News/front/archives/2026/01/21/2003850946

20. 2025–2026 Flu Season | Influenza (Flu) - CDC, accessed January 22, 2026, https://www.cdc.gov/flu/season/2025-2026.html

21. Pre-print: Early influenza virus characterisation and vaccine effectiveness in England in autumn 2025 - GOV.UK, accessed January 22, 2026, https://www.gov.uk/government/publications/pre-print-early-influenza-virus-characterisation-and-vaccine-effectiveness-in-england-in-autumn-2025

22. Early flu virus characterisation and vaccine effectiveness England autumn 2025 - GOV.UK, accessed January 22, 2026, https://assets.publishing.service.gov.uk/media/6924637090a8c154e902625a/_WITHDRAWN__Flu_interimVE_2526.pdf

23. JCVI statement on influenza vaccines for 2025 to 2026 - GOV.UK, accessed January 22, 2026, https://www.gov.uk/government/publications/flu-vaccines-2025-to-2026-jcvi-advice/jcvi-statement-on-influenza-vaccines-for-2025-to-2026

24. Flu, RSV activity rising in US and Europe, with major UK surge in flu cases - CIDRAP, accessed January 22, 2026, https://www.cidrap.umn.edu/influenza-general/flu-rsv-activity-rising-us-and-europe-major-uk-surge-flu-cases